REGENXBIO Inc. (RGNX), a clinical-stage biotechnology company pioneering AAV gene therapies, is preparing to share new interim data from its Duchenne muscular dystrophy program.
The company's lead neuromuscular asset, RGX-202, is a next-generation, one-time gene therapy designed to deliver a novel microdystrophin gene using its NAV AAV8 vector.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com